COX-2 inhibitors and gastric cancer

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Wang, Zhen ^a   Chen, Jun Qiang ^a   Liu, Jin Lu ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; ROFECOXIB;

ALLERGIC REACTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; THROMBUS; UNSTABLE ANGINA PECTORIS;

EID: 84908280096     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2014/132320     Document Type: Review

References (55)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 2-s2.0-78049485263
2. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA: A Cancer Journal for Clinicians 2011 61 2 69 90 10.3322/caac.20107 2-s2.0-79952232216
3. Nagini S., Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World Journal of Gastrointestinal Oncology 2012 4 7 156 169
4. Akre K., Ekström A. M., Signorello L. B., Hansson L. E., Nyrén O., Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. British Journal of Cancer 2001 84 7 965 968 10.1054/bjoc.2001.1702 2-s2.0-0035815222
5. Brown J. R., DuBois R. N., COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology 2005 23 12 2840 2855 10.1200/JCO.2005.09.051 2-s2.0-18444408375
6. Tseng Y.-C., Tsai Y.-H., Tseng M.-J., Hsu K.-W., Yang M.-C., Huang K.-H., Li A. F.-Y., Chi C.-W., Hsieh R.-H., Ku H.-H., Yeh T.-S., Notch2-induced COX-2 expression enhancing gastric cancer progression. Molecular Carcinogenesis 2012 51 12 939 951 10.1002/mc.20865 2-s2.0-84867745527
7. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E. S., Takei Y., Nagano K., Hori M., Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 1998 274 6 G1061 G1067 2-s2.0-0031799475
8. Ristimäki A., Honkanen N., Jänkälä H., Sipponen P., Härkönen M., Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Research 1997 57 7 1276 1280 2-s2.0-0141854494
9. Nardone G., Rocco A., Vaira D., Staibano S., Budillon A., Tatangelo F., Sciulli M. G., Perna F., Salvatore G., di Benedetto M., de Rosa G., Patrignani P., Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori -related gastric carcinogenesis. The Journal of Pathology 2004 202 3 305 312 10.1002/path.1512 2-s2.0-12144289756
10. Wang R., Guo L., Wang P., Yang W., Lu Y., Huang Z., Tang C., Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Current Pharmaceutical Design 2013 19 1 115 125 2-s2.0-84873973938
11. Sun W.-H., Yu Q., Shen H., Ou X.-L., Cao D.-Z., Yu T., Qian C., Zhu F., Sun Y.-L., Fu X.-L., Su H., Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World Journal of Gastroenterology 2004 10 19 2809 2813 2-s2.0-4644318290
12. Konturek P. C., Kania J., Kukharsky V., Ocker S., Hahn E. G., Konturek S. J., Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. Journal of Physiology and Pharmacology 2003 54 1 17 32 2-s2.0-0037344368
13. Compare D., Nardone O., Nardone G., Non-steroidal anti-inflammatory drugs in the carcinogenesis of the gastrointestinal tract. Pharmaceuticals 2010 3 8 2495 2516 10.3390/ph3082495 2-s2.0-77955589143
14. Wu W. K., Yiu Sung J. J., Lee C. W., Yu J., Cho C. H., Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Letters 2010 295 1 7 16 10.1016/j.canlet.2010.03.015 2-s2.0-77953611147
15. Joo Y.-E., Oh W.-T., Rew J.-S., Park C.-S., Choi S.-K., Kim S.-J., Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002 66 4 222 229 10.1159/000068366 2-s2.0-0037910076
16. Thiel A., Mrena J., Ristimäki A., Cyclooxygenase-2 and gastric cancer. Cancer and Metastasis Reviews 2011 30 3-4 387 395 10.1007/s10555-011-9312-1 2-s2.0-83855165726
17. Xue Y.-W., Zhang Q.-F., Zhu Z.-B., Wang Q., Fu S.-B., Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World Journal of Gastroenterology 2003 9 2 250 253 2-s2.0-0037442171
18. Joo Y.-E., Rew J.-S., Seo Y.-H., Choi S.-K., Kim Y.-J., Park C.-S., Kim S.-J., Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. Journal of Clinical Gastroenterology 2003 37 1 28 33 10.1097/00004836-200307000-00009 2-s2.0-0037599444
19. Shi H., Xu J.-M., Hu N.-Z., Xie H.-J., Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World Journal of Gastroenterology 2003 9 7 1421 1426 2-s2.0-0043066734
20. Mrena J., Wiksten J. P., Thiel A., Kokkola A., Pohjola L., Lundin J., Nordling S., Ristimäki A., Haglund C., Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clinical Cancer Research 2005 11 20 7362 7368 10.1158/1078-0432.CCR-05-0764 2-s2.0-27144559175
21. Hofman P., Waidner B., Hofman V., Bereswill S., Brest P., Kist M., Pathogenesis of Helicobacter pylori infection. Helicobacter 2004 9 supplement 1 15 22 10.1111/j.1083-4389.2004.00246.x 2-s2.0-4644229879
22. Konturek P. C., Konturek S. J., Brzozowski T., Helicobacter pylori infection in gastric cancerogenesis. Journal of Physiology and Pharmacology 2009 60 3 3 21 2-s2.0-70350220507
23. Romano M., Ricci V., Memoli A., Tuccillo C., Di Popolo A., Sommi P., Acquaviva A. M., Del Vecchio Blanco C., Bruni C. B., Zarrilli R., Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. The Journal of Biological Chemistry 1998 273 44 28560 28563 10.1074/jbc.273.44.28560 2-s2.0-15644382984
24. 2 synthesis in rat gastric epithelial cells in vitro. Journal of Gastroenterology and Hepatology 2006 21 4 754 758 10.1111/j.1440-1746.2006.04299.x 2-s2.0-33645872990
25. Jankowska H., Hooper P., Jankowski J. A., Aspirin chemoprevention of gastrointestinal cancer in the next decade: a review of the evidence. Polskie Archiwum Medycyny Wewnetrznej 2010 120 10 407 412 2-s2.0-78649616178
26. Jankowski J. A., Hawk E. T., A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nature Clinical Practice Gastroenterology and Hepatology 2006 3 2 101 111 10.1038/ncpgasthep0412 2-s2.0-33645292360
27. Duan L., Wu A. H., Sullivan-Halley J., Bernstein L., Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiology Biomarkers and Prevention 2008 17 1 126 134 10.1158/1055-9965.EPI-07-0664 2-s2.0-38849157724
28. Epplein M., Nomura A. M. Y., Wilkens L. R., Henderson B. E., Kolonel L. N., Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic Cohort study. American Journal of Epidemiology 2009 170 4 507 514 10.1093/aje/kwp162 2-s2.0-68149183960
29. Bosetti C., Rosato V., Gallus S., Cuzick J., la Vecchia C., Aspirin and cancer risk: a quantitative review to 2011. Annals of Oncology 2012 23 6 1403 1415 10.1093/annonc/mds113 2-s2.0-84861722871
30. Ye X., Fu J., Yang Y., Gao Y., Liu L., Chen S., Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS ONE 2013 8 7 e71522 10.1371/journal.pone.0071522 2-s2.0-84880813232
31. Rothwell P. M., Fowkes F. G. R., Belch J. F., Ogawa H., Warlow C. P., Meade T. W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet 2011 377 9759 31 41 10.1016/S0140-6736(10)62110-1 2-s2.0-78650825618
32. Algra A. M., Rothwell P. M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 2012 13 5 518 527 10.1016/S1470-2045(12)70112-2 2-s2.0-84860467522
33. Jankowski J., Hunt R., Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiology Biomarkers and Prevention 2008 17 8 1858 1861 10.1158/1055-9965.EPI-07-0710 2-s2.0-54049086677
34. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Murata H., Hori M., Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. Journal of Clinical Gastroenterology 1998 27 supplement 1 S47 S52 10.1097/00004836-199800001-00009 2-s2.0-0032445736
35. Nam K. T., Hahm K.-B., Oh S.-Y., Yeo M., Han S.-U., Ahn B., Kim Y.-B., Kang J. S., Jang D. D., Yang K.-H., Kim D.-Y., The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori -associated gastric cancer development in a mouse model. Clinical Cancer Research 2004 10 23 8105 8113 10.1158/1078-0432.CCR-04-0896 2-s2.0-9744251631
36. Futagami S., Suzuki K., Hiratsuka T., Shindo T., Hamamoto T., Ueki N., Kusunoki M., Miyake K., Gudis K., Tsukui T., Sakamoto C., Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacology 2007 15 1 1 4 10.1007/s10787-006-1541-5 2-s2.0-33847380188
37. Huang L., Wang C., Zheng W., Liu R., Yang J., Tang C., Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein. Anti-Cancer Drugs 2007 18 9 1075 1080 10.1097/CAD.0b013e3281c49d7a 2-s2.0-34548107571
38. Zhu F. S., Chen X. M., Huang Z. G., Wang Z. R., Zhang D. W., Zhang X., Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. Journal of Digestive Diseases 2010 11 1 34 42 10.1111/j.1751-2980.2009.00411.x 2-s2.0-76349099613
39. Tendo M., Yashiro M., Nakazawa K., Yamada N., Sawada T., Ohira M., Hirakawa K., A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Letters 2006 244 2 247 251 10.1016/j.canlet.2005.12.019 2-s2.0-33749260327
40. Chen M., Yu L., Gu C., Zhong D., Wu S., Liu S., Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Letters 2013 329 2 189 196 10.1016/j.canlet.2012.10.030 2-s2.0-84872496832
41. Ghosh N., Chaki R., Mandal V., Mandal S. C., Cox-2 as a target for cancer chemotherapy. Pharmacological Reports 2010 62 2 233 244 10.1016/S1734-1140(10)70262-0 2-s2.0-77953319891
42. Wang D., Dubois R. N., Prostaglandins and cancer. Gut 2006 55 1 115 122 10.1136/gut.2004.047100 2-s2.0-29244449354
43. Iwamoto J.-I., Mizokami Y., Takahashi K., Matsuoka T., Matsuzaki Y., The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells. Helicobacter 2008 13 3 174 182 10.1111/j.1523-5378.2008.00597.x 2-s2.0-43449100392
44. Maier T. J., Schilling K., Schmidt R., Geisslinger G., Grösch S., Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochemical Pharmacology 2004 67 8 1469 1478 10.1016/j.bcp.2003.12.014 2-s2.0-1642407595
45. Dai Y., Wang W.-H., Non-steroidal anti-inflammatory drugs in prevention gastric cancer. World Journal of Gastroenterology 2006 12 18 2884 2889 2-s2.0-33744479992
46. Funakoshi-Tago M., Shimizu T., Tago K., Nakamura M., Itoh H., Sonoda Y., Kasahara T., Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF- B. Biochemical Pharmacology 2008 76 5 662 671 10.1016/j.bcp.2008.06.015 2-s2.0-49149090886
47. Liu H.-F., Hsiao P.-W., Chao J.-I., Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chemico-Biological Interactions 2008 176 1 48 57 10.1016/j.cbi.2008.07.012 2-s2.0-52949136265
48. Pang R.-P., Zhou J.-G., Zeng Z.-R., Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3 β /NAG-1 pathway. Cancer Letters 2007 251 2 268 277 10.1016/j.canlet.2006.11.032
49. Wu J., Xia H. H. X., Tu S. P., Fan D. M., Lin M. C. M., Kung H. F., Lam S. K., Wong B. C. Y., 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003 24 2 243 247 10.1093/carcin/24.2.243 2-s2.0-0037328659
50. Baoping Y., Guoyong H., Jieping Y., Zongxue R., Hesheng L., Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Digestive Diseases and Sciences 2004 49 6 948 953 10.1023/B:DDAS.0000034553.58554.ab 2-s2.0-3543017329
51. Rostom A., Muir K., Dube C., Lanas A., Jolicoeur E., Tugwell P., Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug, Healthcare and Patient Safety 2009 1 1 47 71 2-s2.0-77749345338
52. Das D., Chilton A. P., Jankowski J. A., Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results in Cancer Research 2009 181 161 168 2-s2.0-61549105593
53. FitzGerald G. A., Coxibs and cardiovascular disease. New England Journal of Medicine 2004 351 17 1709 1711 10.1056/NEJMp048288 2-s2.0-6044274282
54. Feng G. S., Ma J. L., Wong B. C. Y., Zhang L., Liu W. D., Pan K. F., Shen L., Zhang X. D., Li J., Xia H. H., Li J. Y., Lam S. K., You W. C., Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology 2008 14 28 4535 4539 10.3748/wjg.14.4535 2-s2.0-58049089743
55. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. CA: Cancer Journal for Clinicians 2013 63 1 11 30 10.3322/caac.21166 2-s2.0-84872967522